COMMUNIQUÉ DE PRESSE publié le 16/05/2024 à 16:00, il y a 1 année 6 mois Adolore BioTherapeutics Announces Publication Demonstrating Carbonic Anhydrase-8 Gene Therapy (rdHSV-CA8) Decreased Pain-Sensing Neuronal Excitability by Activating Kv7 Voltage-Gated Potassium Channels Adolore BioTherapeutics announces groundbreaking findings in gene therapy for chronic pain treatment, highlighting the value of non-opioid analgesics and progress with IND-enabling studies Adolore BioTherapeutics Chronic Pain Gene Therapy Non-opioid Analgesics IND-enabling Studies
BRÈVE publiée le 04/03/2024 à 16:05, il y a 1 année 9 mois Adolore BioTherapeutics obtient un brevet américain pour la thérapie génique CA8* dans le traitement de la douleur chronique Adolore BioTherapeutics Thérapie Génique Traitement De La Douleur Chronique Solutions Sans Opioïdes Délivrance De Brevet
BRÈVE publiée le 04/03/2024 à 16:05, il y a 1 année 9 mois Adolore BioTherapeutics Secures U.S. Patent for CA8* Gene Therapy in Chronic Pain Treatment Adolore BioTherapeutics Gene Therapy Chronic Pain Treatment Opioid-Free Solutions Patent Issuance
COMMUNIQUÉ DE PRESSE publié le 04/03/2024 à 16:00, il y a 1 année 9 mois Adolore BioTherapeutics Announces Issuance of First U.S. Patent Covering CA8* Gene Therapies to Treat Chronic Pain Adolore BioTherapeutics licenses patent and CA8* gene therapy technology from the University of Miami for opioid-free chronic pain treatment. Company progresses toward clinical testing and commercialization University Of Miami Adolore BioTherapeutics Chronic Pain Opioid-free Gene Therapy
COMMUNIQUÉ DE PRESSE publié le 30/01/2024 à 16:00, il y a 1 année 10 mois Adolore BioTherapeutics to Present at the 5th Annual National Institutes of Health (NIH) HEAL Initiative Scientific Meeting Adolore BioTherapeutics will present at the 5th Annual NIH HEAL Initiative Scientific Meeting regarding the gene therapy program for chronic pain associated with knee osteoarthritis. The program is supported by NIH/NINDS HEAL UH3 Award Adolore BioTherapeutics Chronic Pain NIH HEAL Initiative Gene Therapy Osteoarthritis
COMMUNIQUÉ DE PRESSE publié le 05/12/2023 à 16:30, il y a 1 année 11 mois Adolore BioTherapeutics Presents Promising Preclinical Data Supporting Its Innovative Gene Therapy to Treat Chronic Pain Adolore BioTherapeutics presented preclinical data supporting its innovative CA8* gene therapy as a long-acting local analgesic for chronic osteoarthritis knee pain management, aiming to replace opioids Adolore BioTherapeutics CA8* Gene Therapy Chronic Pain Opioid-free Preclinical Data
COMMUNIQUÉ DE PRESSE publié le 11/10/2023 à 16:00, il y a 2 années 1 mois Adolore BioTherapeutics to Participate at the Virtual Investor Ask the CEO Conference
COMMUNIQUÉ DE PRESSE publié le 03/10/2023 à 15:15, il y a 2 années 2 mois NIN/NINDS HEAL Program Grants Prestigious UH3 Award to the University of Miami, Principal Investigator Roy C. Levitt M.D, to Fund Clinical Development of Adolore BioTherapeutics’ Gene Therapy Program for the Treatment of Chronic Osteoarthritis Knee Pain
Publié le 04/12/2025 à 18:14, il y a 13 heures 38 minutes Résiliation d'une convention conclue entre actionnaires
Publié le 04/12/2025 à 18:00, il y a 13 heures 52 minutes Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025
Publié le 04/12/2025 à 18:00, il y a 13 heures 52 minutes Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Publié le 04/12/2025 à 17:45, il y a 14 heures 7 minutes Informations relatives au nombre total de droits de vote et d’actions
Publié le 04/12/2025 à 17:45, il y a 14 heures 7 minutes MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Publié le 05/12/2025 à 02:35, il y a 5 heures 17 minutes Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Publié le 05/12/2025 à 01:00, il y a 6 heures 52 minutes BEACN Closes First Tranche of Non-Brokered Private Placement
Publié le 04/12/2025 à 23:05, il y a 8 heures 47 minutes BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Publié le 04/12/2025 à 23:00, il y a 8 heures 52 minutes NXT Energy Solutions Completes Data Acquisition for SFD Survey
Publié le 05/12/2025 à 07:00, il y a 52 minutes Swiss Re targets a net income of USD 4.5 billion in 2026; refreshed strategy to strengthen core business
Publié le 05/12/2025 à 03:30, il y a 4 heures 22 minutes CGTN: What makes cooperation between China and France a two-way success
Publié le 04/12/2025 à 23:50, il y a 8 heures 1 minute EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Publié le 04/12/2025 à 20:25, il y a 11 heures 27 minutes Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Publié le 04/12/2025 à 20:15, il y a 11 heures 37 minutes Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025